10.12.19

Kodiak Sciences Announces Data from Ongoing Phase 1b Study of KSI-301 in Patients With Wet AMD, DME and RVO

Source: Kodiak Sciences

10.09.19

Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Francisco

Source: Oxurion NV

10.08.19

Genentech/Roche Complete Enrollment in YOSEMITE and RHINE Phase 3 Studies of Faricimab in DME

Source: Genentech

10.07.19

Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAO

Source: Kodiak Sciences

09.04.19

Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687 for the Treatment of DME

Source: Oxurion NV

09.03.19

Oxurion to Make a Late-Breaker Presentation of Topline THR-149 Phase 1 Clinical Data at EURETINA

Source: Oxurion

08.20.19

Oxurion Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 in Combination with Ranibizumab for DME

Source: Oxurion NV

08.20.19

Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Wet AMD and DME

Source: Aerie Pharmaceuticals

08.05.19

Alimera Announces Iluvien Regulatory Approval in Australia for the Treatment of DME

Source: Alimera Sciences

08.01.19

Perspective: Protocol V Sheds Light on Managing Mild Diabetic Macular Edema

Source: Medscape

View more stories